Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents
Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents
批准号:
7903199
负责人:
HAIDEN A. HUSKAMP
金额:
$47.85万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2012-07-31
关键词:
AddressAdministratorAdoptionAdverse eventAffectAngiotensin ReceptorAntidepressive AgentsBedsBehaviorCardiacCaringCholinesterase InhibitorsChronicCognitiveCommunitiesDataData SetDelusionsDrug CostsDrug FormulationsDrug InteractionsDrug PrescriptionsDrug UtilizationElderlyEnrollmentFormulariesFractureHallucinationsHandHealthHome Nursing CareHospitalizationImpaired cognitionIndividualInhalant dose formLeast-Squares AnalysisLifeLilly brand of olanzapineLinear RegressionsLinkLiteratureLogistic RegressionsLong-Term CareLow incomeMeasuresMedicaidMedicalMedicareMedicare Part AMedicare/MedicaidMedication ErrorsModelingModernizationNursing HomesOpioidOral cavityOsteoporosisOutcomePainPerformancePersonal SatisfactionPharmaceutical PreparationsPharmacy facilityPhysiciansPoliciesPolypharmacyPopulationQuality of CareRandomizedRelative (related person)ReportingResearchResourcesSelection BiasStagingStructural ModelsTechniquesTimeWorkatypical antipsychoticbasebeneficiarycostdepressive symptomsdual eligiblefunctional outcomesfunctional statusimprovedinterestolanzapineprior authorizationpublic health relevancereceptor
中文摘要
描述(由申请人提供):Medicare Part D处方药福利极大地改变了疗养院对处方药的融资和管理方式,特别是对三分之二同时有资格享受Medicare和Medicaid(“双重资格”)的居民。虽然医疗补助以前涵盖双重资格疗养院居民的药物,但这些人现在被随机分配到私人处方药计划(PDP)。PDP在特定药物的处方复盖面和使用管理技术方面各不相同。因此,一些符合双重条件的养老院居民被随机分配到PDP,他们目前的药物覆盖范围很大,而另一些人则被随机分配到PDP,覆盖范围更有限。目前还没有关于PDP慷慨对具有双重资格的养老院居民的健康和福祉影响的实证研究。为了评估PDP慷慨对药物使用和居民健康结果的影响,我们建议使用来自一家大型长期护理药房的药物利用数据,并结合最低数据集(MDS)和联邦医疗保险A部分住院索赔的2005年至2008年期间(实施D部分之前一年和之后三年)的健康结果数据。本申请的具体目的是:1)构建针对具有双重资格的疗养院居民被随机分配到的每个PDP的保险慷慨程度的药物特定测量;2)检查PDP慷慨对药物改变和停用的影响;3)检查PDP慷慨对健康结果的影响;以及4)评估药物改变和停止用药对健康结果的影响。目标2和目标3利用PDP的双重符合条件的随机化来评估慷慨对药物使用和结果的影响,这些影响不受选择偏见的影响。为了确定药物中断是否是PDP慷慨影响健康结果的一种机制,目标4使用对PDP的随机分配作为结构模型中的工具变量,估计药物变化和停药对健康结果的影响。我们将检查医生、疗养院管理人员和长期护理药房报告的七类药物对某些PDP的覆盖限制:骨质疏松症药物、血管紧张素受体阻滞剂(ARB)、非典型抗精神病药物、抗抑郁药物、胆碱酯酶抑制剂、长效阿片类药物和雾化吸入剂。我们将研究可能与中断使用这些药物有关的健康结果,包括骨折、心脏并发症住院、幻觉或妄想、行为、抑郁症状、认知表现、功能状态和疼痛。我们将估计三项回归模型、Logistic回归模型、线性回归模型和两阶段最小二乘回归模型的组合来实现这些目标。公共卫生相关性:根据联邦医疗保险D部分,具有双重资格的老年疗养院居民--具有巨大医疗需求但财政资源有限的人群--被随机分配到PDP,而不考虑其当前药物的覆盖范围。我们的研究将首次对PDP覆盖范围、慷慨程度对双重资格养老院居民的药物使用和健康结果的影响进行全面评估。这项研究的结果将有助于联邦和州政策制定者评估D部分可能的变化,以及其他负责住院护理的关键利益攸关方,如疗养院管理员、护理养老院居民的医生和长期护理药房。
英文摘要
DESCRIPTION (provided by applicant): The Medicare Part D prescription drug benefit dramatically changed how prescription drugs are financed and administered in nursing homes, particularly for the two-thirds of residents who are dually eligible for Medicare and Medicaid ("dual eligibles"). While Medicaid formerly covered drugs for dual-eligible nursing home residents, these individuals are now randomly assigned to private prescription drug plans (PDP). PDPs vary with respect to formulary coverage and utilization management techniques for specific medications. As a result, some dual-eligible nursing home residents are randomized to PDPs with generous coverage of their current medications and others to PDPs with more restrictive coverage. There have been no empirical studies of the impact of PDP generosity on the health and well-being of dual-eligible nursing home residents. To assess the impact of PDP generosity on medication use and resident health outcomes, we propose to use drug utilization data from a large long term care pharmacy in combination with data on health outcomes from the Minimum Data Set (MDS) and Medicare Part A hospitalization claims for the period 2005-2008 (one year before and three years after Part D implementation). The specific aims of this application are to: 1) construct medication-specific measures of the generosity of coverage for each PDP to which a dual-eligible nursing home resident was randomly assigned; 2) examine the impact of PDP generosity on medication changes and discontinuations; 3) examine the impact of PDP generosity on health outcomes; and 4) assess the impact of medication changes and discontinuations on health outcomes. Aims 2 and 3 take advantage of the randomization of dual eligibles to PDPs to estimate effects of generosity on medication use and outcomes that are uncontaminated by selection bias. To determine if medication disruptions are a mechanism through which PDP generosity affects health outcomes, Aim 4 uses the random assignment to PDPs as an instrumental variable in a structural model estimating the effect of medication changes and discontinuations on health outcomes. We will examine seven classes of medications for which physicians, nursing home administrators, and long term care pharmacies have reported coverage restrictions for some PDPs: osteoporosis medications, angiotensin receptor blockers (ARBs), atypical antipsychotics, antidepressants, cholinesterase inhibitors, long-acting opioids, and nebulized inhalants. We will study health outcomes that could be related to disruptions in use of these medications, including fractures, hospitalization for cardiac complications, hallucinations or delusions, behavior, depressive symptoms, cognitive performance, functional status, and pain. We will estimate a combination of trinomial regression models, logistic regression models, linear regression models, and two-stage least squares regression models to address these aims. PUBLIC HEALTH RELEVANCE: Under Medicare Part D, elderly dual-eligible nursing home residents -- a population with great medical need and limited financial resources -- are randomly assigned to a PDP without consideration of its coverage of their current medications. Our study will provide the first comprehensive assessment of the impact of PDP coverage generosity on medication use and health outcomes for dual-eligible nursing home residents. The results of this study will be useful to federal and state policymakers in assessing possible changes to Part D and to other key stakeholders responsible for resident care, such as nursing home administrators, physicians who care for nursing home residents, and long term care pharmacies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Medications for Alcohol Use Disorder: Unfilled Prescriptions and Treatment Trajectories
-
批准号:10436953
-
项目类别:
-
资助金额:$80.58万
-
财政年份:2021
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Medications for Alcohol Use Disorder: Unfilled Prescriptions and Treatment Trajectories
-
批准号:10598575
-
项目类别:
-
资助金额:$81.0万
-
财政年份:2021
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Telemedicine for Treatment of Opioid Use Disorder
-
批准号:10169552
-
项目类别:
-
资助金额:$17.46万
-
财政年份:2019
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Telemedicine for Treatment of Opioid Use Disorder: NIDA Summer Research Internship Program
-
批准号:10402983
-
项目类别:
-
资助金额:$1.06万
-
财政年份:2019
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Telemedicine for Treatment of Opioid Use Disorder
-
批准号:10382265
-
项目类别:
-
资助金额:$72.9万
-
财政年份:2019
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Telemedicine for Treatment of Opioid Use Disorder
-
批准号:10152467
-
项目类别:
-
资助金额:$91.31万
-
财政年份:2019
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Use of Telemedicine in the Treatment of Mental Illness
-
批准号:10442011
-
项目类别:
-
资助金额:$87.15万
-
财政年份:2017
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Use of Telemedicine in the Treatment of Mental Illness
-
批准号:10599349
-
项目类别:
-
资助金额:$76.83万
-
财政年份:2017
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Center to Improve System Performance of Substance Use Disorder Treatment
-
批准号:10494628
-
项目类别:
-
资助金额:$141.68万
-
财政年份:2015
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Core-004
-
批准号:10672047
-
项目类别:
-
资助金额:$35.42万
-
财政年份:2015
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Core-005
-
批准号:10672048
-
项目类别:
-
资助金额:$35.42万
-
财政年份:2015
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Comparative Effectiveness of Treatment Regimens in Lung Cancer
-
批准号:8842077
-
项目类别:
-
资助金额:$24.66万
-
财政年份:2014
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Technology Diffusion and New Delivery Models
-
批准号:8626757
-
项目类别:
-
资助金额:$46.82万
-
财政年份:2013
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Technology Diffusion Pathways
-
批准号:9136864
-
项目类别:
-
资助金额:$57.71万
-
财政年份:2013
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Technology Diffusion Pathways
-
批准号:8916466
-
项目类别:
-
资助金额:$58.04万
-
财政年份:2013
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Technology Diffusion and New Delivery Models
-
批准号:8743290
-
项目类别:
-
资助金额:$56.55万
-
财政年份:2013
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents
-
批准号:7695302
-
项目类别:
-
资助金额:$46.49万
-
财政年份:2009
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents
-
批准号:8106160
-
项目类别:
-
资助金额:$43.54万
-
财政年份:2009
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Effects of Mental Parity on High-Cost and Severely-Ill Individuals
-
批准号:7576323
-
项目类别:
-
资助金额:$41.31万
-
财政年份:2008
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
Effects of Mental Parity on High-Cost and Severely-Ill Individuals
-
批准号:7742675
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2008
-
负责人:HAIDEN A. HUSKAMP
-
依托单位:
海外基金